Early post-treatment MRI predicts long-term hepatocellular carcinoma response to radiation segmentectomy.
Carcinoma, hepatocellular
Liver neoplasms
Magnetic resonance imaging
Yttrium radioisotopes
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
04 Aug 2023
04 Aug 2023
Historique:
received:
21
02
2023
accepted:
20
06
2023
revised:
29
05
2023
medline:
4
8
2023
pubmed:
4
8
2023
entrez:
4
8
2023
Statut:
aheadofprint
Résumé
Radiation segmentectomy using yttrium-90 plays an emerging role in the management of early-stage HCC. However, the value of early post-treatment MRI for response assessment is uncertain. We assessed the value of response criteria obtained early after radiation segmentectomy in predicting long-term response in patients with HCC. Patients with HCC who underwent contrast-enhanced MRI before, early, and 12 months after radiation segmentectomy were included in this retrospective single-center study. Three independent radiologists reviewed images at baseline and 1 Eighty patients (M/F 60/20, mean age 67.7 years) with 80 HCCs were assessed (median size baseline, 1.8 cm [IQR, 1.4-2.9 cm]). At 12 months, 74 patients were classified as CR (92.5%), 5 as partial response (6.3%), and 1 as progressive disease (1.2%). Diagnostic accuracy for predicting CR was fair to good for all readers with excellent positive predictive value (PPV): mRECIST (range between 3 readers, accuracy: 0.763-0.825, PPV: 0.966-1), LI-RADS TRA (accuracy: 0.700-0.825, PPV: 0.983-1), and subtraction (accuracy: 0.775-0.825, PPV: 0.967-1), with no difference in accuracy between criteria (p range 0.053 to > 0.9). mRECIST, LI-RADS TRA, and subtraction obtained on early post-treatment MRI show similar performance for predicting long-term response in patients with HCC treated with radiation segmentectomy. Response assessment extracted from early post-treatment MRI after radiation segmentectomy predicts complete response in patients with HCC with high PPV (≥ 0.96). • Early post-treatment response assessment on MRI predicts response in patients with HCC treated with radiation segmentectomy with fair to good accuracy and excellent positive predictive value. • There was no difference in diagnostic accuracy between mRECIST, LI-RADS, and subtraction for predicting HCC response to radiation segmentectomy.
Identifiants
pubmed: 37540318
doi: 10.1007/s00330-023-10045-z
pii: 10.1007/s00330-023-10045-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576
doi: 10.1053/j.gastro.2007.04.061
pubmed: 17570226
Global Burden of Disease Cancer C, Fitzmaurice C, Allen C et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 3:524–548
doi: 10.1001/jamaoncol.2016.5688
European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236
doi: 10.1016/j.jhep.2018.03.019
Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380
doi: 10.1002/hep.29086
pubmed: 28130846
National Comprehensive Cancer Network (2020) Hepatobiliary cancer (version 3.2020). Available via https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary_blocks.pdf . Accessed 1 June 2020
Kim E, Sher A, Abboud G et al (2022) Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol 7:843–850
doi: 10.1016/S2468-1253(22)00091-7
pubmed: 35617978
Lewandowski RJ, Gabr A, Abouchaleh N et al (2018) Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology 287:1050–1058
doi: 10.1148/radiol.2018171768
pubmed: 29688155
Salem R, Gilbertsen M, Butt Z et al (2013) Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 11(1358–1365):e1351
Salem R, Gordon AC, Mouli S et al (2016) Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151(1155–1163):e1152
Salem R, Lewandowski RJ, Kulik L et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140(497–507):e492
Gordic S, Corcuera-Solano I, Stueck A et al (2017) Evaluation of HCC response to locoregional therapy: validation of MRI-based response criteria versus explant pathology. J Hepatol 67:1213–1221
doi: 10.1016/j.jhep.2017.07.030
pubmed: 28823713
Kim S, Mannelli L, Hajdu CH et al (2010) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 31:348–355
doi: 10.1002/jmri.22038
pubmed: 20099348
Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60
doi: 10.1055/s-0030-1247132
pubmed: 20175033
American Collge of Radiology (2018) CT/MRI LI-RADS version 2018. Available via https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018 . Accessed 03/08/2021
Prajapati HJ, Spivey JR, Hanish SI et al (2013) mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 24:965–973
doi: 10.1093/annonc/mds605
pubmed: 23223331
Singh P, Anil G (2014) Yttrium-90 radioembolization of liver tumors: what do the images tell us? Cancer Imaging 13:645–657
doi: 10.1102/1470-7330.2013.0057
pubmed: 24434228
pmcid: 3893902
Hectors SJ, Lewis S, Kennedy P et al (2020) Assessment of hepatocellular carcinoma response to (90)Y radioembolization using dynamic contrast material-enhanced MRI and intravoxel incoherent motion diffusion-weighted imaging. Radiol Imaging Cancer 2:e190094
doi: 10.1148/rycan.2020190094
pubmed: 32803165
pmcid: 7398117
Kennedy P, Lewis S, Bane O et al (2021) Early effect of (90)Y radioembolisation on hepatocellular carcinoma and liver parenchyma stiffness measured with MR elastography: initial experience. Eur Radiol 31:5791–5801
doi: 10.1007/s00330-020-07636-5
pubmed: 33475773
Sato Y, Watanabe H, Sone M et al (2013) Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci 118:16–22
doi: 10.3109/03009734.2012.729104
pubmed: 23167460
pmcid: 3572665
Shropshire EL, Chaudhry M, Miller CM et al (2019) LI-RADS treatment response algorithm: performance and diagnostic accuracy. Radiology 292:226–234
doi: 10.1148/radiol.2019182135
pubmed: 31038409
King MJ, Tong A, Dane B, Huang C, Zhan C, Shanbhogue K (2020) Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. Eur J Radiol 133:109351
doi: 10.1016/j.ejrad.2020.109351
pubmed: 33096408
Klompenhouwer EG, Dresen RC, Verslype C et al (2018) Transarterial radioembolization following chemoembolization for unresectable hepatocellular carcinoma: response based on apparent diffusion coefficient change is an independent predictor for survival. Cardiovasc Intervent Radiol 41:1716–1726
doi: 10.1007/s00270-018-1991-3
pubmed: 29872894
Kokabi N, Camacho JC, Xing M et al (2014) Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis. Abdom Imaging 39:969–978
doi: 10.1007/s00261-014-0127-8
pubmed: 24740759
Rhee TK, Naik NK, Deng J et al (2008) Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 19:1180–1186
doi: 10.1016/j.jvir.2008.05.002
pubmed: 18656011
Vouche M, Salem R, Lewandowski RJ, Miller FH (2015) Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC? Abdom Imaging 40:1471–1480
doi: 10.1007/s00261-014-0295-6
pubmed: 25412868
Rhee TK, Omary RA, Gates V et al (2005) The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma. J Vasc Interv Radiol 16:1085–1091
doi: 10.1097/01.RVI.0000177063.92678.21
pubmed: 16105920
Riaz A, Gates VL, Atassi B et al (2011) Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 79:163–171
doi: 10.1016/j.ijrobp.2009.10.062
pubmed: 20421150
Vouche M, Habib A, Ward TJ et al (2014) Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 60:192–201
doi: 10.1002/hep.27057
pubmed: 24691943
Fleiss JL (1971) Measuring nominal scale agreement among many raters. Psychol Bull 76:378–382
doi: 10.1037/h0031619
Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174
doi: 10.2307/2529310
pubmed: 843571
Salem R, Johnson GE, Kim E et al (2021) Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: The LEGACY Study. Hepatology 74:2342–2352
doi: 10.1002/hep.31819
pubmed: 33739462
Lee JS, Choi HJ, Kim BK et al (2020) The Modified Response Evaluation Criteria in Solid Tumors (RECIST) yield a more accurate prognoses than the RECIST 1.1 in hepatocellular carcinoma treated with transarterial radioembolization. Gut Liver 14:765–774
doi: 10.5009/gnl19197
pubmed: 32050313
pmcid: 7667935
Ormiston WEL, Yarmohammadi H, Lobaugh S et al (2020) Post-treatment CT LI-RADS categories: predictors of overall survival in hepatocellular carcinoma post bland transarterial embolization. Abdom Radiol (NY). https://doi.org/10.1007/s00261-020-02775-1
doi: 10.1007/s00261-020-02775-1
pubmed: 32968863
Ibrahim SM, Nikolaidis P, Miller FH et al (2009) Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging 34:566–581
doi: 10.1007/s00261-008-9454-y
pubmed: 18777189
Kielar A, Fowler KJ, Lewis S et al (2018) Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY) 43:218–230
doi: 10.1007/s00261-017-1281-6
pubmed: 28780679
Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A et al (2015) Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology 62:1111–1121
doi: 10.1002/hep.27915
pubmed: 25999236
ViettiVioli N, Gnerre J, Law A et al (2022) Assessment of HCC response to yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology. Eur Radiol. https://doi.org/10.1007/s00330-022-08732-4
doi: 10.1007/s00330-022-08732-4
Kong C, Zhao Z, Chen W et al (2021) Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE. Eur Radiol 31:7500–7511
doi: 10.1007/s00330-021-07910-0
pubmed: 33860832
pmcid: 8452577
Moawad AW, Fuentes D, Khalaf AM et al (2020) Feasibility of automated volumetric assessment of large hepatocellular carcinomas’ responses to transarterial chemoembolization. Front Oncol 10:572
doi: 10.3389/fonc.2020.00572
pubmed: 32457831
pmcid: 7221016
Ince O, Onder H, Gencturk M, Cebeci H, Golzarian J, Young S (2023) Prediction of response of hepatocellular carcinoma to radioembolization: machine learning using preprocedural clinical factors and MR imaging radiomics. J Vasc Interv Radiol 34(235–243):e233